Cowen analyst Doug Schenkel raised his price target on DexCom to $175 from $150 following its “blowout” Q4 results. The analyst believes its guidance leaves plenty of room for top and bottom line upside, though he admits a new competitor product could provide headline risk. He views the shares as a long-term core holding. Schenkel reiterated his Outperform rating on DexCom shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.